Osteoporosis Market Report and Forecast 2025-2034

The osteoporosis market size in the 7 major markets was valued at USD 13.90 Billion in 2024, driven by increasing innovations and research activities. The market size is anticipated to grow at a CAGR of 3.58% during the forecast period of 2025-2034 to achieve a value of USD 19.76 Billion by 2034.

Osteoporosis Market Overview

Osteoporosis can be characterized by low bone mass, deterioration of bone tissue, bone sterility, and constant risk of fracturing the bones. The most common cause of a broken bone among the elderly is osteoporosis. Bones that are most affected by the condition include the vertebrae in the spine, forearm, the wrist, and the hip. This condition typically exhibits no symptoms until it is diagnosed during the examination of a fractured bone. It makes it hard for the patients to carry out regular daily life activities as a little amount of pressure or stress may result in a broken bone.

The development of new, more effective osteoporosis medications, and advancements in bone density testing, is also driving the osteoporosis market growth. Government support and initiatives aimed at improving bone health and lowering the incidence of osteoporosis-related fractures are also fuelling the market growth.

Prevalence of Osteoporosis to Drive the Market Growth

The market is expected to witness significant growth driven by the increase in the incidence of osteoporosis. According to the International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually, resulting in a fracture every three seconds around the world. The market growth can be further attributed to the growing investment in research and development activities conducted by biotechnology and pharmaceutical companies. The increasing public awareness of the condition is also playing a crucial role in the increasing number of diagnoses, contributing to the osteoporosis market share. Moreover, the market is expected to be driven by the rising technological advancements and drug development, likely to bolster the market growth during the forecast period.

Innovations Expected to Bolster Market Growth

The market is expected to witness significant growth driven by ground-breaking innovations and developments in the forecast period. For instance, in June 2023, the development of a robotic pill that safely delivers injectable osteoporosis drugs. The highly encouraging efficacy has offered hope to individuals suffering from chronic conditions, such as osteoporosis, as the only route of administration currently available is painful injections. This pioneering technology has the potential to revolutionize treatment options for patients, providing a painless alternative to injections.

Technical Advancements to Bolster the Demand

The market growth is expected to be driven by the new technologically advanced developments, exemplified by the development of OsteoBoost by Bone Health Technologies. It is a vibration belt designed to fight osteoporosis and osteopenia. OsteoBoost has been developed on 15 years of published research, including research from NASA. Bone Health Technologies has filed for Class 2 Prescription De Novo Approval with the FDA. Such developments attract investors which plays a crucial role in the market development and stability, likely to aid the osteoporosis market size in the forecast period.

Government Initiatives to Aid the Growth

Additionally, increasing initiatives and efforts by non-government organizations towards creating awareness and providing solutions are collectively contributing to osteoporosis market growth. For instance, in Feb 2023, the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) signed an agreement to develop a strategic roadmap on bone health and aging and advocate for a public health strategy to prevent fractures among older people. This partnership with WHO is expected to enhance the prevention and management of osteoporosis at local, regional, and national levels resulting in an enhanced quality of life for individuals living with this condition.

Increasing Research and Clinical Trials Leading New Opportunities

The increasing number of clinical trials to examine the efficacy of a drug is a major factor responsible for the growth of the osteoporosis market value. In May 2023, new research showed how women taking romosozumab, a new anti-osteoporosis drug available on the NHS, might be at risk of a heart attack. The University of Bristol-led study analysed the genetic data on about 34,000 people. Romosomuzab is an effective medicine prescribed to women with severe osteoporosis to reduce the risk of fracture. Discoveries like this are expected to spark discussion among healthcare professionals and researchers to perform more research and find the truth. Additionally, it sparks competition in the market as it brings opportunities for pharmaceutical companies to develop more suitable drugs with no side effects and high efficacy, boosting the market size.

Osteoporosis Market Segmentations

Osteoporosis Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

• Primary Osteoporosis
• Secondary Osteoporosis

Market Breakup by Therapy

• Bisphosphonates
• Selective Estrogen Receptor Modulators
• Parathyroid Hormone Therapy
• RANK Ligand Inhibitors

Market Breakup by Route of Administration

• Oral
• Injectable
• Others

Market Breakup by End User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Market Breakup by Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan

Osteoporosis Market Analysis

The United States is dominating the market and is expected to continue dominating the market during the forecast period driven by the presence of key players and the high prevalence of osteoporosis patients in the region. The presence of a robust and high-tech healthcare infrastructure, coupled with the availability of advanced drugs, is expected to drive the osteoporosis market growth.

In November 2023, Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the approval of a generic version of Forteo in the United States. Teva's generic equivalent of Forteo (teriparatide injection) utilizes the Antares Pharma, Inc. multi-dose pen device. Teriparatide injection is indicated to treat osteoporosis among certain women and men. Such announcements indicate more affordable options becoming available for treating osteoporosis and accessible to people in need. More affordable options can potentially increase access to osteoporosis treatment, leading to growing demand for these medications.

Osteoporosis Market: Competitor Landscape

In May 2023, Amgen announced that Prolia® (denosumab) injection has been found effective in reducing the risk of fractures in postmenopausal women compared to a common pill treatment called oral alendronate. The announcement was based on new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program. The treatment was also associated with greater reductions in fracture risk over time. Consequentially, doctors and patients are expected to prefer Prolia due to the promising long-term results. This announcement could also encourage further research and development of similar treatments, making more options available to help manage osteoporosis effectively.

The key features of the osteoporosis market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• DAIICHI SANKYO COMPANY
• Amgen Inc.
• Merck & Co., Inc
• AbbVie Inc
• Bayer AG
• Johnson & Johnson Services, Inc.
• Sanofi.
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Astrazeneca
• Eli Lilly And Company
• Novartis AG
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc.

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

This product will be delivered within 3-5 business days.